We are pleased to announce the launch of the collaborative development project on autologous antigen-presenting cell cancer immunotherapy between our company and Shangrila Bio Co., Ltd (Gwangju Metropolitan City, Republic of Korea. CEO: 朴 炫璟. Hereafter referred to as SB), which has started from Apri...

AMBICION Co., Ltd announced that RIKEN and AMBICION acquired the new patent “Technology for Efficient Activation of NKT Calls” in Japan.
This patent acquisition enforces the exclusivity of its business regarding the Natural Killer T (NKT) cell-targeted cancer therapy. Patent No 447947 Dat...

AMBICION participates in Regenerative Medicine JAPAN 2018 (held with Bio Japan 2018) as an exhibitor on October 10 to 12. (Booth number: R-22)
We’re looking forward to seeing you at our booth. For more information
Regenerative Medicine JAPAN 2018 ...